Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.

Wolf DM, Yau C, Campbell M, Glas A, Barcaru A, Mittempergher L, Kuilman M, Brown-Swigart L, Hirst G, Basu A, Magbanua M, Sayaman R, Huppert L, Delson A, I-SPY2 Investigators, Symmans WF, Borowsky A, Pohlmann P, Rugo H, Clark A, Yee D, DeMichele A, Perlmutter J, Petricoin EF, Chien J, Stringer-Reasor E, Shatsky R, Liu M, Han H, Soliman H, Isaacs C, Nanda R, Hylton N, Pusztai L, Esserman L, van 't Veer L

Open source

DOI: 10.1200/po-24-00776
Published: 2025 Jun
Container: JCO precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/po-24-00776,
  title = {Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.},
  author = {Wolf DM and Yau C and Campbell M and Glas A and Barcaru A and Mittempergher L and Kuilman M and Brown-Swigart L and Hirst G and Basu A and Magbanua M and Sayaman R and Huppert L and Delson A and I-SPY2 Investigators and Symmans WF and Borowsky A and Pohlmann P and Rugo H and Clark A and Yee D and DeMichele A and Perlmutter J and Petricoin EF and Chien J and Stringer-Reasor E and Shatsky R and Liu M and Han H and Soliman H and Isaacs C and Nanda R and Hylton N and Pusztai L and Esserman L and van 't Veer L},
  year = {2025},
  journal = {JCO precision oncology},
  doi = {10.1200/po-24-00776},
  url = {https://doi.org/10.1200/po-24-00776}
}

RIS

TY  - JOUR
TI  - Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
AU  - Wolf DM
AU  - Yau C
AU  - Campbell M
AU  - Glas A
AU  - Barcaru A
AU  - Mittempergher L
AU  - Kuilman M
AU  - Brown-Swigart L
AU  - Hirst G
AU  - Basu A
AU  - Magbanua M
AU  - Sayaman R
AU  - Huppert L
AU  - Delson A
AU  - I-SPY2 Investigators
AU  - Symmans WF
AU  - Borowsky A
AU  - Pohlmann P
AU  - Rugo H
AU  - Clark A
AU  - Yee D
AU  - DeMichele A
AU  - Perlmutter J
AU  - Petricoin EF
AU  - Chien J
AU  - Stringer-Reasor E
AU  - Shatsky R
AU  - Liu M
AU  - Han H
AU  - Soliman H
AU  - Isaacs C
AU  - Nanda R
AU  - Hylton N
AU  - Pusztai L
AU  - Esserman L
AU  - van 't Veer L
PY  - 2025
JO  - JCO precision oncology
DO  - 10.1200/po-24-00776
UR  - https://doi.org/10.1200/po-24-00776
ER  -

APA

DM, W., C, Y., M, C., A, G., A, B., L, M., M, K., L, B., G, H., A, B., M, M., R, S., L, H., A, D., Investigators, I., WF, S., A, B., P, P., H, R., A, C., D, Y., A, D., J, P., EF, P., J, C., E, S., R, S., M, L., H, H., H, S., C, I., R, N., N, H., L, P., L, E., & L, V. '. V. (2025). Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.. JCO precision oncology. https://doi.org/10.1200/po-24-00776

Source records

pubmed · retrieved 2026-09-26T13:32:08.977Z